For instance, inhibition of HER2/HER3 heterodimer signalling either by shHER3 mediated knock-down or pertuzumab/trastuzumab treatment was correlated with markedly reduced growth of BT474M1 and MDA-MB-175 induced tumours in vivo [49]. The gene discussed is ERBB3; the disease is neoplasm.